New asthma therapy at Hochgebirgsklinik Davos

The Hochgebirgsklinik Davos, as a partner of the Allergy Campos Davos, treats allergic diseases as a priority. Davos offers a healthy climate and the air is low in allergens and pollutants.

Asthma is a complex, highly heterogeneous disease with various phenotypes of respiratory inflammation. Since June 2016 injections of an interleukin-5 antibody instead of cortisone have been given in Switzerland to patients with very severe eosinophilic asthma. The concept of anti-IL-5 treatment has proved clinically beneficial in asthma with severe eosinophilic airway inflammation.

The treatment received its licence in Switzerland in June 2016 and, in special cases of severe bronchial asthma, can markedly improve the symptoms and reduce the exacerbation rate (asthma attacks). On 11 August 2016 a patient with severe eosinophilic asthma was the first to be injected with an interleukin-5 antibody (mepolizumab) at the Hochgebirgsklinik Davos. IL-5 is a cytokine which plays an important role in the development, activation, differentiation and survival of eosinophils.

After the decision to treat and application by a lung specialist, the treatment costs for mepolizumab (Nucala) are met by the cost bearers for patients with a specific subgroup of difficult-to-treat bronchial asthma (“eosinophilic asthma”).

Prof. Hans-Werner Duchna would be very happy to provide you with detailed information about this treatment. On request, the medical service of HGK will support you in the application process or the formalities of obtaining confirmation of insurance coverage.

Prof Dr. med. H.W. Duchna, Ärztlicher Direktor, Chefarzt Pneumologie/Allergologie
Tel. +41 81 417 33 13
hans-werner.duchna@hgk.ch
www.hochgebirgsklinik.ch

Certification by the Swiss Biobanking Platform – VITA-Label

Building up a proper Governance through accountable mechanisms is key to foster trustworthiness and the pre-requisite for the appropriate use of biological resources. Our CK-CARE Biobank has recently been awarded by Swiss Biobanking Platform (SBP) with the VITA Label, which demonstrates compliance with the applicable legal and ethical framework. This labelling approach is part of our long-term strategy to strengthen biobanking practices and provide high-quality samples to the research community.

CK-CARE Team Meeting October 10th- 11th, 2022

This year’s CK-CARE team event in Davos focused on strengthening cross-center communication and collaboration. Our team members learned more about each other and the canton Graubünden by producing several Grison specialties «Cross-center team building» to prepare the scientific work.

Embarking on this journey made all the difference in promoting real teamwork! Despite the fact none of us really knew how to make these Grison delicacies let alone had the relevant skills, each team excelled in their own unique way. Driven by trust, respect and a genuine motivation to solve the given tasks, team members rose to the challenge of collaboration with fun and creativity. All vital ingredients to the following day research acitivities.

It has been a truly remarkable meeting – we look forward to many more.

Certification by the Swiss Biobanking Platform – OPTIMA-Label

Davos BioSciences AG achieved the official OPTIMA label of the Swiss Biobanking Platform for its biobank infrastructure as of 30.05.2022. This is another important step for Davos BioSciences AG and CK-CARE. The label attests to the full implementation of a QM system. The OPTIMA-Label confirms: “Compliance with the Good Biobanking Practices; in particular OECD Best practice guidelines for biological resource centres (2007), ISBER Best practices (2018) and IARC Common minimum technical standards (2017). It follows established standards, including the ISO 20387:2018 – general requirements for biobanking. This certification approach is part of our long-term strategy to provide high-quality samples to the research community”.

Certification by the Swiss Biobanking Platform

After some effort, Davos BioSciences AG achieved the official NORMA label of the Swiss Biobanking Platform for its biobank infrastructure as of 17.08.2021. This is an important step for Davos BioSciences AG and CK-CARE. The NORMA-Label confirms: “Compliance with professional standards is essential to perform our daily biobanking activities according to Good Biobanking Practices; in particular OECD Best practice guidelines for biological resource centres (2007), ISBER Best practices (2018) and IARC Common minimum technical standards (2017). It follows established standards, including the ISO 20387:2018 – general requirements for biobanking. This certification approach is part of our long-term strategy to provide high-quality samples to the research community”. Certificate of the Swiss Biobanking Plattform

Claudio Rhyner, PhD appointed as the new Managing Director

On 1 October 2020, Claudio Rhyner succeeded Dr. Georg Schäppi as Managing Director of CK-CARE. Georg Schäppi was appointed CEO at the University Children’s Hospital Zurich as of 1 December, 2020.

Claudio Rhyner was born and grew up in Davos. After studying chemistry and molecular biology, he graduated specialising in asthma and allergy research. He was active in fundamental scientific research, including as head of the research “Vaccine Development” group at the SIAF (Swiss Institute of Allergy and Asthma Research). In this capacity he published numerous publications and filed several patents. After holding a leading position in a SME in molecular diagnostics, he became CEO of Biosciences Davos. Biosciences Davos is a spin-off organisation of CK-CARE in the field of biobanking and is part of the Medizincampus Davos. He continues to hold this position.

In his private life, Claudio Rhyner is actively engaged in politics and culture in the Davos community. He also completed a postgraduate degree in the field of management of small and medium-sized companies at the University St. Gallen.

Atopic dermatitis: an expanding therapeutic pipeline for a complex disease

Our founder, Prof. Thomas Bieber, published an important contribution in the treatment of AD:

Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing to the limited response to available therapies. However, recent advances in understanding of disease mechanisms have led to the discovery of novel potential therapeutic targets and drug candidates

In addition to regulatory approval for the IL-4Ra inhibitor dupilumab, the anti-IL-13 inhibitor tralokinumab and the JAK1/2 inhibitor baricitinib in Europe, there are now more than 70 new compounds in development. This Review assesses the various strategies and novel agents currently being investigated for AD and highlights the potential for a precision medicine approach to enable prevention and more effective long-term control of this complex disease.

read more…